ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
36 announcements with these filters
Orchid Pharma Ltd intimated that its board will meet on November 14, 2026 to consider Q2 and half-year unaudited results. The trading window stays closed until 48 hours after results declaration.
Orchid Pharma entered a licensing and supply agreement with Laboratorio Libra for Exblifep across nine Latin American markets. The partnership is expected to represent a potential opportunity of about USD 80 million over 10 years.
Orchid Pharma's board approved an enabling resolution to raise funds of up to ₹600 Crore through equity or debt securities via various permissible modes.
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Orchid Pharma has scheduled a board meeting for October 20, 2026, to consider options for raising funds. The company will explore various suitable funding avenues.
Orchid Pharma Ltd has filed its quarterly Shareholding Pattern, providing a routine update on promoter and public shareholding as mandated by SEBI regulations.
Orchid Pharma held its 33rd Annual General Meeting on September 29, 2026, where shareholders considered and approved routine business resolutions and related party transactions.
Orchid Pharma Limited received trading approval for 4,45,86,052 equity shares issued under its NCLT-sanctioned scheme of amalgamation, effective September 23, 2026.
Orchid Pharma purchased land in Patibulum Village, Kancheepuram District. This transaction concludes the previous lease arrangement with DBS Bank regarding the property.
Orchid Pharma has filed its Annual Report for the financial year 2025-26, which includes the notice for the company's 33rd Annual General Meeting.
Orchid Pharma Limited has issued the notice for its 33rd Annual General Meeting scheduled for September 29, 2026, to conduct ordinary and special business.
Orchid Pharma Limited announced the redesignation of Mr. Arjun Dhanuka as Executive Director and the appointment of M/s. J Karthikeyan & Associates as Cost Auditors.
Orchid Pharma appointed a cost auditor and designated Mr. Arjun Dhanuka as a Whole-Time Director. The board also set arrangements for the upcoming 33rd Annual General Meeting.
Orchid Pharma's Q1FY27 revenue grew 15% YoY to INR 304Cr, with EBITDA rising to INR 25Cr. The company is pivoting toward complex, high-value molecules and backward integration.
Management reports a recovery in Q1 FY27 with 15% revenue growth after a difficult FY26, but remains cautious due to industry-wide overcapacity and pricing pressure.
Orchid Pharma reported strong Q1FY27 performance following the strategic amalgamation of Dhanuka Laboratories, transforming into an integrated cephalosporin platform with a significant turnaround in profitability metrics.
Orchid Pharma filed its Monitoring Agency Report for the quarter ended June 30, 2026, as per SEBI regulations regarding its prior QIP issue.
Orchid Pharma Ltd reported revenue from operations of ₹368.3 Cr (+3.0% YoY) and net profit of ₹25.8 Cr (-24.1% YoY) for Q4 FY26.
Orchid Pharma Ltd reported revenue from operations of ₹304.2 Cr (+15.6% YoY) and net profit of ₹3.2 Cr for Q1 FY27.
Orchid Pharma Limited has scheduled a board meeting for August 14, 2026, to consider and approve its Q1 FY 2026-27 financial results and restated annual results.
Orchid Pharma allotted 4,45,86,052 equity shares to shareholders of Dhanuka Laboratories Limited, following the approved scheme of amalgamation.
Orchid Pharma has scheduled a board meeting for August 1, 2026, to approve share allotments related to the amalgamation with Dhanuka Laboratories Limited.
Orchid Pharma Ltd has filed its quarterly shareholding pattern as of June 30, 2026, disclosing the promoter and public shareholding distribution.
Orchid Pharma announced that the merger of Dhanuka Laboratories Limited is now effective. Dhanuka Laboratories stands dissolved following the filing of NCLT orders with the ROC.
Orchid Pharma signed a licensing deal with Russia's Pharmasyntez, unlocking a $178M opportunity. This 10-year pact for Exblifep® marks a major international expansion for the Indian pharma firm.
Orchid Pharma received a Rs.1.67 Crore GST demand for an erroneously refunded amount. The company believes the order is unjustified and plans to appeal.
NCLT Chennai has sanctioned the merger of Dhanuka Laboratories Limited with Orchid Pharma Limited. This approval facilitates the legal consolidation of operations and assets on a going-concern basis.
Orchid Pharma reports FY26 standalone revenue of ₹811cr and EBITDA of ₹101cr. Strategy shifts towards platform creation, including the Dhanuka merger and entering the U.S. sterile formulation market.
Orchid Pharma Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report details statutory compliance status and historical observations.
Orchid Pharma is pivoting from a recovery phase to a higher-margin 'platform creation' model, integrating Dhanuka Laboratories and aggressively targeting the US sterile cephalosporin market.